Navigation Links
Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market

MOUNTAIN VIEW, Calif., June 6, 2013 /PRNewswire/ -- Based on its recent analysis of the oncology market, Frost & Sullivan recognizes Sorrento Therapeutics, Inc. (OTCBB: SRNE); (Sorrento) with the 2013 Global Frost & Sullivan Investment Opportunity Award. In a pharmaceutical industry that is crowded with early stage competitors aiming to develop monoclonal antibodies (mAbs) or other novel therapeutics in oncology, Sorrento believes it has gained an edge through a combination of factors, including its diverse mAb library, experienced management team, and superior ability to select and rapidly develop promising drug targets, such as fully human anti-PD-L1 and anti-PD-1 mAbs.

One of Sorrento's key differentiators is its robust intellectual property (IP). Its extensive patent portfolio, which positions it to develop next-generation targeted therapeutics and nanomedicines, includes issued patents and filed patent applications for its lead product candidate Cynviloq™, G-MAB® library, its human G-MAB®-derived mAbs and TOCOSOL®-PAC, as well as groundbreaking platform technologies such as antibody formulated drug conjugates (AfDC) and recombinant intravenous immunoglobulin (rIVIG). Sorrento, through its pending acquisition of IGDRASOL, Inc. has obtained the exclusive marketing and distribution rights to Cynviloq™ in the United States and the 27 EU member countries. Cynviloq™ is patent protected worldwide by Samyang Biopharmaceutical Corporation, a South Korean corporation, until 2028, preventing competitors from using similar processes to create competitive therapeutics.

Cynviloq™ has pharmacokinetic (PK) properties amenable to personalized dosing, allowing for an improved therapeutic index when compared to industry leader Abraxane®, which is marketed by Celgene Corporation. Sorrento plans to exploit Cynviloq™ potential bioequivalence (BE) to Abraxane® to get Cynviloq™ to the market quickly and at minimal cost using the FDA 505(b)(2) BE application pathway that allows companies to obtain FDA approval of new drug applications (NDAs) for reformulations of drugs with the same active ingredient.

"Sorrento is unique in its ability to potentially have an approved oncology product within the next few years using an abbreviated 505(b)(2) BE pathway at a fraction of the cost of what is spent by traditional drug development companies," noted Frost & Sullivan Industry Analyst Justin Collishaw . "Our independent analysis confirms that other competitors lack similar near-term approvable therapies, which may be able to generate revenues in the next three to four years."

Sorrento, through its IGDRASOL acquisition, also secured EU distribution rights, which give Sorrento the flexibility to form alliances with multinational companies seeking late-stage drug products to fill in gaps in their pipeline. In addition, Sorrento is moving forward in the field of true personalized medicine with the development of Therapeutic Drug Monitoring (TDM), which will complement and expand the Cynviloq™ franchise in the market.

Sorrento's next strength lies in its outstanding management team that boasts an impressive track record of long-term vision and timely execution. Such an industry-leading management team will help Sorrento's valuable products reach their full potential.

"Partnership with large pharma could accelerate Sorrento's development program and broaden its portfolio into inflammation and infectious diseases," noted Collishaw. "As a publicly traded company, Sorrento has the added advantage of access to the public investment market."

Sorrento is further consolidating its market position by targeting therapeutic areas with an unmet need. The company is selecting antibody candidates that have strong market potential, such as

PD-L1, PD-1, as well as G protein-coupled receptor (GPCR) antibodies for immunotherapy in oncology. It is also improving upon already approved therapies through its proprietary AfDC process. This enables Sorrento to capitalize on the familiarity and success of predecessors, such as Herceptin® or Erbitux®, while competitors are developing therapies from scratch, thus creating greater difficulty in establishing familiarity.

Overall, Sorrento's strength of IP, expert management team, funding history, market growth and positioning, expansion strategy, and product differentiation capabilities make it a worthy recipient of the 2013 Frost & Sullivan Global Investment Opportunity Award.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company focused on the acquisition, discovery, development and commercialization of novel and proprietary therapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, and infectious diseases. Sorrento's objective is to develop and commercialize its late-stage, oncolytic drug candidate – Cynviloq™ – for multiple cancer indications, to identify drug development candidates derived from its proprietary human antibody libraries and, either independently or through partnerships, advance selected targets into preclinical or clinical development. Sorrento intends to select several lead product candidates to progress into preclinical development activities in 2013, including human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) that have demonstrated strong immunomodulatory activity in vitro comparable to competitor mAbs currently in clinical development as well as significant anti-cancer activity in a tumor mouse model.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:        Gain access to visionary innovation


Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):